TransCode's RNA Therapy Shows Promise Against Deadly Brain Cancer

TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage biotech company, has announced a significant breakthrough in cancer treatment with the publication of peer-reviewed preclinical research supporting its lead candidate, TTX-MC138, for glioblastoma multiforme—one of the most aggressive and deadly forms of brain cancer. The study, conducted in collaboration with Michigan State University and published in the Journal of Functional Biomaterials, demonstrated that systemic delivery of TTX-MC138 successfully reached brain tumors in orthotopic glioblastoma models, significantly increased tumor cell apoptosis, and resulted in a statistically significant improvement in survival. These findings validate TransCode's innovative TTX delivery platform and support the potential advancement of TTX-MC138 into future clinical trials for glioblastoma patients, building on completed IND-enabling studies and existing Phase 1 clinical experience outside the central nervous system.

TransCode Therapeutics is pioneering immunoncology and RNA therapeutic treatments for high-risk and advanced cancers, with TTX-MC138 specifically targeting metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The company's portfolio includes other first-in-class candidates designed to mobilize the immune system against cancer. This research, accessible via the full press release, underscores the potential of RNA-based therapies in oncology. BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN, distributed this news, highlighting its role in delivering breaking developments in biotechnology and life sciences to investors and the public through enhanced press release distribution and social media outreach.

The implications of this study are profound, as glioblastoma multiforme has historically had limited treatment options and poor survival rates, making any therapeutic advance a critical step forward. By leveraging its TTX platform, TransCode aims to address unmet medical needs in oncology, potentially offering new hope for patients with aggressive cancers. The collaboration with academic institutions like Michigan State University further strengthens the scientific credibility of these findings. For more updates on RNAZ, investors can visit the company's newsroom, while BioMedWire continues to provide comprehensive coverage of biotech innovations, ensuring that such groundbreaking news reaches a wide audience through its network of wire solutions and syndication partners.